Dartmouth-Hitchcock Medical Center
This pilot study aims to investigate the viability of using a smartwatch-based electrodermal activity (EDA) sensor to capture enough EDA signal to quantitatively assess pain in osteoarthritis subjects and test the feasibility of its methods and procedures for later use in subsequent larger-scale studies.
Chronic pain, a disease in its own right, afflicts one in three adults in the US and poses an enormous economic burden ($560-$635 billion annually), more than heart disease, cancer, and diabetes. To treat pain, doctors often prescribe opioids to suffering patients. Paradoxically, prescription opioid abuse has become a national epidemic, costing $500 billion annually in medical, economic, social, and criminal ramifications. However, the development of effective treatment for chronic pain is hampered by the lack of a reliable biomarker that can quantify the level of pain and detect any attenuati…
Study subjects Inclusion Criteria: * Kellgren-Lawrence Grade \>= 3 Exclusion Criteria: * Inflammatory arthropathy (e.g., rheumatoid arthritis), BMI \>=35 Control subjects: Exclusion Criteria: * Complaints of lower extremity joint pain * Known diagnosis of knee osteoarthpathy * Prior history of knee surgery, knee injections, or injury to knee joints (e.g., meniscus tears, ligamentous injuries), BMI \>=35 Both groups, exclusion: * Subjects with chronic heart problems, including, but not limited to, chronic hypertension, heart palpitations, a weak or irregular heartbeat, or a previous he…
Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.
Arctuva estimate
Verify or correct the compensation shown for this listing.